RNS Number : 6446A
Genedrive PLC
16 April 2026

16 April 2026

genedrive plc

("genedrive" or the "Company")

Implementation of Genedrive® CYP2C19 ID Kit in North Bristol NHS Trust Southmead Hospital

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to report that implementation of its CYP2C19 ID kit at Bristol NHS Trust Southmead Hospital's Hyperacute and Acute Stroke Units is expected to commence shortly.

Southmead Hospital (NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board (ICB)) treats approximately 1,500 stroke patients per year, and funding of £80k for the implementation has been provided to it by the Medlock Charitable Trust (Medlockcharitabletrust.org), of which David Medlock, a significant shareholder of genedrive, is Chair.

The funding will be administered through Southmead Hospital Charity, the official charity of North Bristol NHS Trust. The charity has a long-standing role in supporting enhancements to patient care across the Trust, going beyond what the NHS alone can provide.

Business case preparation by Southmead Stroke Services will progress in parallel with the aim of securing local ICB funding for the continued provision of the CYP2C19 test post the initial implementation period.

Dr Gino Miele, CEO of genedrive plc, said: *"We are grateful to David and the Medlock Charitable Trust for providing the funding that enables implementation of our CYP2C19 rapid genetic test at Southmead Hospital. As a result of this support, stroke patients in the region will immediately benefit from optimised antiplatelet therapy whilst genedrive continues to engage with the ICB to secure the longer-term provision of this life saving test."*

David Medlock, Chair, Medlock Charitable Trust, said*: "It's a privilege to help equip our local NHS stroke medicine service with cutting edge technology which will not only help patients but also save money."*

Professor Tim Whittlestone, Bristol NHS Group Chief Medical and Innovation Officer, said: "*We are pleased to have the support of genedrive, which enables us to introduce point-of-care clopidogrel genotype testing within our service. This approach to stroke secondary prevention allows for more individualised treatment decisions, helping us improve long-term outcomes for our diverse Bristol patient population.****"***

genedrive plc	+44 (0)161 989 0245
Gino Miele: CEO / Russ Shaw: CFO	https://investors.genedrive.com/s/e0025c

Peel Hunt LLP (Nominated Adviser and Broker)	+44 (0)20 7418 8900
James Steel	
5654 & Company (Media & Investor Relations)	genedrive@5654.co.uk
Matthew Neal	+44 (0)7917 800 011
Melissa Gardiner	+44 (0)7757 697357

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03

About genedrive plc (http://www.genedrive.com**).**

genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.

genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention

The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.

Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSFSFMIEMSEEL